U.S. Entertainment Stock News

NasdaqGS:CHA
NasdaqGS:CHAHospitality

Is It Time To Reassess Chagee Holdings (NasdaqGS:CHA) After Recent Share Price Softness?

If you are wondering whether Chagee Holdings at US$12.09 offers good value or is priced for perfection, you are in the right place to get a clear, valuation focused view. Over the short term the stock has seen a 0.4% decline over 7 days, a 2.9% decline over 30 days, and a 1.8% decline year to date, which may have shifted how some investors see its risk and opportunity. Recent coverage has centered on Chagee Holdings as it gains attention as a listed tea focused consumer services business...
NYSE:NATL
NYSE:NATLDiversified Financial

NCR Atleos Epirus Bank ATMaaS Deal Tests Growth Versus Valuation Concerns

NCR Atleos (NYSE:NATL) has partnered with Epirus Bank in Greece to modernize the bank's ATM network. The agreement introduces a branded ATM as a Service model using the Atleos platform and Cashzone network. The partnership is intended to expand cash access and improve self-service banking for Epirus Bank customers across Greece. NCR Atleos focuses on self-service banking technology and ATM outsourcing, and this new agreement with Epirus Bank provides another data point on how its ATMaaS...
NasdaqGS:METC
NasdaqGS:METCMetals and Mining

Jefferies Upgrade Puts Ramaco’s Coal And Rare Earth Story In Focus

Jefferies has upgraded Ramaco Resources (NasdaqGS:METC) from Hold to Buy. The upgrade is linked to potential upside in metallurgical coal prices. Jefferies also points to positive sentiment around Ramaco's Brook Mine rare earth project. Geopolitical developments are a key part of the thesis behind the new rating. Ramaco Resources is a producer of metallurgical coal used primarily in steelmaking. Any shift in coal pricing can quickly change how investors view the stock. The new rating from...
NYSE:CMA
NYSE:CMABanks

Comerica (CMA) Premium P E Challenges Modest Earnings Growth Narrative After FY 2025 Results

Comerica (CMA) just wrapped up FY 2025 with fourth quarter revenue of US$836 million and basic EPS of US$1.28, supported by trailing twelve month revenue of US$3.27 billion and EPS of US$5.33. Over recent periods, the bank has seen revenue move from US$3.20 billion and EPS of US$5.05 in the twelve months to Q4 2024 to US$3.27 billion and EPS of US$5.33 in the latest twelve month stretch, giving investors a clearer read on how earnings and top line are tracking together. With a trailing net...
NasdaqCM:RR
NasdaqCM:RRMachinery

Richtech Robotics (RR) Heavy Q4 Loss Per US$1.4 Million Revenue Undermines Growth Narrative

Richtech Robotics FY 2025 Earnings Snapshot Richtech Robotics (RR) closed FY 2025 with Q4 revenue of US$1.4 million and a basic EPS loss of US$0.02, as net income excluding extra items came in at a loss of US$3.6 million. This result sets the stage for another year of rebuilding the path toward profitability. The company reported quarterly revenue moving from US$1.3 million in Q1 2025 to US$1.4 million in Q4 2025, while basic EPS ranged between a loss of US$0.04 and a loss of US$0.02 across...
NasdaqGM:CSTL
NasdaqGM:CSTLHealthcare

How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth

In January 2026, Castle Biosciences reported that 2025 total revenue is expected to exceed US$340 million, above its prior US$327–US$335 million range, alongside strong year-on-year growth in test volumes for its core DecisionDx-Melanoma and TissueCypher Barrett’s Esophagus assays. The sharp increase in core test reports, particularly for TissueCypher, suggests that Castle’s efforts to broaden clinical adoption and utilization are gaining traction across its key diagnostic franchises. Now...